Drug developer BiVictriX Therapeutics has a low capital cost model which outsources the main operations. The company also works with the University of Liverpool and Swansea University. BVX001 has already indicated an anti-tumour effect in animal models. No adverse effects were observed. The cash raised will accelerate the optimisation of BVX001, so it reaches pre-clinical […]

The post New AIM admission: BiVictriX developing unique cancer treatments appeared first on UK Investor Magazine.